The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Open accessAbstract
Comparison 1 AI versus non-AI, Outcome 1 Overall survival (reported or calculated). . . . . . .Analysis 1.2.Comparison 1 AI versus non-AI, Outcome 2 Progression-free survival (reported or calculated). . . .Analysis 1.3.Comparison 1 AI versus non-AI, Outcome 3 Clinical benefit (assessable). . . . . . . . . . . .Analysis 1.4.Comparison 1 AI versus non-AI, Outcome 4 Objective response (assessable). . . . . . . . . .Analysis 1.5.Comparison 1 AI versus non-AI, Outcome 5 Clinical benefit (randomised). . . . . . . . . . .Analysis 1.6.Comparison 1 AI versus non-AI, Outcome 6 Objective response (randomised). . . . . . . . . .Analysis 2.1.Comparison 2 AI versus non-AI: Toxicity, Outcome 1 hot flushes. . . . . . . . . . . . . .Analysis 2.2.Comparison 2 AI versus non-AI: Toxicity, Outcome 2 nausea. . . . . . . . . . . . . . . .Analysis 2.3.Comparison 2 AI versus non-AI: Toxicity, Outcome 3 vomiting. . . . . . . . . . . . . . .Analysis 2.4.Comparison 2 AI versus non-AI: Toxicity, Outcome 4 diarrhoea. . . . . . . . . . . . . . .Analysis 2.5.Comparison 2 AI versus non-AI: Toxicity, Outcome 5 rash. . . . . . . . . . . . . . . .Analysis 2.6.Comparison 2 AI versus non-AI: Toxicity, Outcome 6 vaginal bleeding. . . . . . . . . . . .Analysis 2.7.Comparison 2 AI versus non-AI: Toxicity, Outcome 7 thromboembolic. . . . . . . . . . . .Analysis 2.8.Comparison 2 AI versus non-AI: Toxicity, Outcome 8 arthralgia. . . . . . . . . . . . . . .Analysis 3.1.Comparison 3 Current AIs versus non-AI, Outcome 1 Overall survival (reported or calculated). . . .Analysis 3.2.Comparison 3 Current AIs versus non-AI, Outcome 2 Progression-free survival (reported or calculated).Analysis 3.3.Comparison 3 Current AIs versus non-AI, Outcome 3 Clinical benefit (assessable). . . . . . . .Analysis 3.4.Comparison 3 Current AIs versus non-AI, Outcome 4 Objective response (assessable). . . . . . .Analysis 3.5.Comparison 3 Current AIs versus non-AI, Outcome 5 Clinical benefit (randomised). . . . . . . .Analysis 3.6.Comparison 3 Current AIs versus non-AI, Outcome 6 Objective response (randomised). . . . . .Analysis 4.1.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 1 hot flushes. . . . . . . . . . .Analysis 4.2.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 2 nausea. . . . . . . . . . . .Analysis 4.3.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 3 vomiting. . . . . . . . . . .Analysis 4.4.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 4 diarrhoea. . . . . . . . . . .Analysis 4.5.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 5 rash. . . . . . . . . . . . .Analysis 4.6.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 6 vaginal bleeding. . . . . . . . .Analysis 4.7.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 7 thromboembolic. . . . . . . . .Analysis 4.8.Comparison 4 Current AIs versus non-AI: Toxicity, Outcome 8 arthralgia. . . . . . . . . . .Analysis 5.1.Comparison 5 AI versus different AI, Outcome 1 Overall survival (reported). . . . . . . . . .Analysis 5.2.Comparison 5 AI versus different AI, Outcome 2 Progession-free survival (reported or calculated). . .Analysis 5.3.Comparison 5 AI versus different AI, Outcome 3 Clinical benefit (assessable). . . . . . . . . .Analysis 5.4.Comparison 5 AI versus different AI, Outcome 4 Objective response (assessable). . . . . . . . .Analysis 5.5.Comparison 5 AI versus different AI, Outcome 5 Clinical benefit (randomised). . . . . . . . .Analysis 5.6.Comparison 5 AI versus different AI, Outcome 6 Objective response (randomised). . . . . . . .Analysis 6.1.Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 1 Overall survival (reported or calculated). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 6.2.Comparison 6 AI as first-line therapy versus any other therapy (tamoxifen), Outcome 2 Progression-free survival (reported or calculated). . . . . . . . . . . . . . . . . . . . . . . . . . . .i Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72384-7 · Cited by 1,608
Globocan 2000 : cancer incidence, mortality and prevalence worldwide
Ferlay, J., Pisani, P., & Parkin, D. M. (2001) · Medical Entomology and Zoology · Cited by 1,579
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72307-0 · Cited by 1,282
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Cited by
Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0044 · Cited by 529
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Metadata
- Authors
- Gibson, L., Lawrence, D., Dawson, C., & Bliss, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-10-07
- Volume
- 2021
- Issue
- 2
- Pages
- CD003370-CD003370
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1946355969
- Cited by
- 252
- References
- 82
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. https://app.cochat.ai/papers/10.1002/14651858.cd003370.pub3
- The paper
- Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009). Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003370.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.